Binge-Eating Disorder (BED), Emotional Eating, Food Chatter, and Overweight affect millions of Americans both psychologically and physically
Dr. Sheenie Ambardar, MD is an award-winning psychiatrist, psychotherapist, and coach who serves patients throughout California and New York via telehealth. Dr. Ambardar has training and certification in Medical Weight Management from the International Association for Physicians in Aesthetic Medicine (IAPAM) - approved by the American Academy of Family Physicians (AAFP).
The use of GLP-1 agonists (GLP-1s) in the treatment of binge-eating disorder, emotional eating, overweight, and food chatter offers much hope and promise to those who have struggled with these debilitating lifelong issues.
Dr. Ambardar is among a handful of clinical psychiatrists at the forefront of utilizing GLP-1 agonists to target both the psychological and physical aspects of binge-eating, emotional eating, overweight, and food chatter.
At The Happiness PsychiatristⓇ, we provide expert, award-winning treatment for a range of mental health conditions. Via services such as integrative psychiatry and holistic psychotherapy, we treat Binge-Eating Disorder (BED), emotional eating, food chatter, and:
Reach out today to discover how you can begin your journey to a more fulfilled, happier self.
In this article, we explore recent GLP-1 studies as well as the efficacy of GLP-1 therapy for binge eating. We answer all of your questions including:
Let’s dive in!
GLP-1 receptor agonists (GLP-1s), also known as incretin mimetics, are a group of medications frequently used for managing Type 2 diabetes. Recent research has shown promising potential for their use in weight management, binge-eating disorder, and emotional eating.
GLP-1 agonists, such as semaglutide (Ozempic®, Wegovy®), liraglutide (Saxenda®), and GLP-1/GIP agonists such as tirzepatide (Mounjaro®, Zepbound®), work by mimicking the action of the GLP-1 and/or GIP hormones.
The main function of these hormones is to stimulate insulin secretion, slow stomach emptying, and lower blood glucose levels. GLP-1 agonists like Ozempic® and Wegovy® also have effects on the brain, specifically on brain areas associated with reward and appetite regulation. These medications work to decrease appetite as well as decrease food cravings/food chatter, making them potential candidates for treating eating disorders like binge-eating disorder (BED).
GLP-1s have garnered attention for their potential to address underlying issues related to appetite regulation, food consumption, and treating obesity. In recent years, research has shed light on the multifaceted benefits of GLP-1s in helping individuals regain control over their eating habits and make significant strides towards achieving a healthier body weight and overall well-being. In this exploration, we delve into the various advantages of using GLP-1s as a therapeutic treatment for those facing complex dietary struggles, shedding light on the potential for:
Let’s examine the benefits of GLP-1s, how they influence appetite and food-related behaviors, as well as their potential side effects.
GLP-1s slow stomach emptying which can help enhance feelings of satiety or fullness, which in turn aids with weight management. Several studies have demonstrated significant weight loss in overweight or obese individuals treated with GLP-1s.
The enhanced feeling of satiety associated with GLP-1s can also improve binge eating behaviors. By helping individuals feel fuller sooner and for longer periods of time, these medications can potentially reduce the frequency and severity of binge eating episodes.
GLP-1s may help reduce persistent, intrusive thoughts about food often referred to as "food chatter." The exact mechanism for this effect is not entirely clear but may be linked to how these medications influence hunger and satiety signals in the brain. This can result in reduced psychological preoccupation with food and help people better control their eating behaviors.
GLP-1s can also have positive impacts on overall metabolic health and reduce risk factors for diseases like Type 2 diabetes and heart disease. By aiding weight loss, improving glycemic control, and potentially even directly acting on fat cells and the cardiovascular system, these medications may contribute to improved metabolic profiles.
Although more research is needed, there are indications that GLP-1s may have positive psychological benefits. Some patients report improved mood and decreased anxiety related to food, which could be linked to an overall reduction in food chatter and improved control over eating behaviors.
While all medications carry some risk of side effects, GLP-1s tend to have a favorable side effect profile, especially when compared to other weight-loss medications. The most common side effects are gastrointestinal (nausea, diarrhea, vomiting) and typically decrease over time.
It's important to remember that while GLP-1s can be an effective tool for managing weight and eating behaviors, they are not a standalone solution. Medications such as Ozempic®, Wegovy®, Mounjaro®, and Zepbound® should be used in conjunction with lifestyle changes, including healthy eating and regular physical activity. Additionally, these medications may not be suitable for everyone and any potential benefits need to be weighed against potential risks. Always consult your physician for personalized medical advice.
Are you interested in trying GLP-1 Therapy for Binge-Eating Disorder, Emotional Eating, Food Chatter, or Overweight? Learn more about Dr. Ambardar's psychologically-focused Medical Weight Care Services and Fees
The landscape of medical interventions for weight management and metabolic health has expanded significantly in recent years, and medications like Ozempic®, Wegovy®, Mounjaro®, Zepbound®, and Saxenda® have shown remarkable promise in the treatment of obesity, type 2 diabetes, and related metabolic disorders.
However, the question of who should consider GLP-1 therapy is a nuanced one, with various factors influencing its suitability for individuals. We take a look at the criteria and considerations that healthcare providers and patients should weigh when contemplating GLP-1 therapy. These include:
GLP-1s are not suitable for everyone, including those with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. These medications also come with potential side effects, most commonly gastrointestinal symptoms.
Patients considering GLP-1 therapy should always consult with their physician to discuss potential risks and benefits. Any decision to start GLP-1 medications should be based on a comprehensive evaluation of the individual's overall health status, personal medical history, and treatment goals.
At The Happiness Psychiatrist®, GLP-1s are prescribed by Dr. Ambardar as part of an integrated treatment plan that may include psychotherapy, health and wellness coaching, dietary changes, exercise, and other lifestyle and behavioral modifications.
More than enough false and unsupported claims about weight-loss medication exist in the diet and exercise industry to fill a flagship GNC. So, are GLP-1s legitimate or just another sales ploy? We’ll let the digital stacks of research below answer that for you:
•Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity
•Once-Weekly Semaglutide in Adults with Overweight or Obesity
•A pilot randomized controlled trial of liraglutide 3.0 mg for binge eating disorder
•Weight-Loss Drugs Like Ozempic Are Treating Binge Eating, Too
•Dulaglutide Reduces Binge Eating in Patients With T2D and Binge Eating Disorder
•Tirzepatide Once Weekly for the Treatment of Obesity
•Wegovy (semaglutide): a new weight loss drug for chronic weight management
•Liraglutide for psychiatric disorders: clinical evidence and challenges
The use of GLP-1 agonists in the treatment of binge-eating disorder, emotional eating, overweight, and food chatter offers much hope and promise to those who have struggled with these debilitating lifelong issues.
Dr. Ambardar is among a handful of clinical psychiatrists at the forefront of utilizing GLP-1 agonists to target both the psychological and physical aspects of binge-eating, emotional eating, overweight, and food chatter.
This is an exciting time for the field and the future of psychiatric medicine will likely see more cross-disciplinary treatments like this, where drugs initially developed for metabolic disorders find utility in treating psychiatric conditions.
As always, any medication decisions should be made with the supervision and collaboration of your physician. If you think GLP-1 therapy might be helpful to you, I encourage you to contact our office.
And if you're ready to get started today, please go ahead and fill out our confidential Medical Weight Management Intake Form and read about our Medical Weight Care Services and Fees.
Interested in more from The Happiness Psychiatrist®? Check out these blog posts next: